FDA grants AP status for Saptalis' Sonazine (Chlorpromazine Hydrochloride)
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Sonazine, a chlorpromazine hydrochloride product from Saptalis Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Sonazine with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.